Compare Adaptive Biotechnologies Corp (ADPT) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Otis Worldwide Corp — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Otis Worldwide Corp trades at $72.41 (market cap $28.18B). The key difference: Otis Worldwide Corp is far larger — about 8.5× Adaptive Biotechnologies Corp's market cap, and Otis Worldwide Corp pays a 2.32% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | OTIS | |
|---|---|---|
Market Cap | $3.33B | $28.18B |
Sector | Health | Industrials |
52-Week High | $22.37 | $101.07 |
52-Week Low | $10.24 | $69.34 |
Enterprise Value | $3.19B | $35.56B |
Dividend Yield | — | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
OTIS trades at $73.43, up 0.4% today, with a bullish technical signal and strong support at $72. The company reported $14.43B in 2025 revenue, a 10.11% net income margin, and a P/E of 19.55. Recent news highlights elevator modernization projects and a 5% dividend increase to $0.44 per share. Earnings have been mixed, with a Q1 2026 miss but service segment growth.
The stock offers a 28% upside to the $94 consensus price target, supported by buybacks and dividend growth, but faces risks from high debt and margin pressure. Analyst sentiment is mixed with 38% buy ratings. Execution on service growth and cost management is critical for re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
